By using air pressure data and PM(10) concentration measurements,

By using air pressure data and PM(10) concentration measurements, the quantitative relationship between pressure variability and PK variation in different

sections of the anticyclone was established. A linear relationship was assumed between PM(10) variation Adriamycin inhibitor per unit area in the mixing layer and pressure variation within a time interval, and different sections of the anticyclone were associated with different linear regression equations. A parameter called PM(10) variation rate was then put forward, which could be easily applied for regional air pollution control and management. (C) 2011 Elsevier Ltd. All rights reserved.”
“Introduction: This study compared survival after initial treatment with esophagectomy as primary therapy to induction therapy followed by

esophagectomy for patients with clinical T2N0 (cT2N0) esophageal cancer in the National Cancer Database (NCDB). Methods: Predictors of therapy selection for patients with cT2N0 esophageal cancer in the NCDB from 1998 to 2011 were identified with multivariable logistic regression. Survival was evaluated using Kaplan-Meier and Cox proportional Microtubule Associat inhibitor hazards methods. Results: Surgery was used in 42.9% (2057

of 4799) of cT2N0 patients. Of 1599 esophagectomy patients for whom treatment timing was recorded, induction therapy was used in 44.1% (688). Pretreatment staging was proven accurate in only 26.7% of patients (210 of 786) who underwent initial surgery without induction treatment and had complete pathologic data MDV3100 nmr available: 41.6% (n = 327) were upstaged and 31.7% (n = 249) were downstaged. Adjuvant therapy (chemotherapy or radiation therapy) was given to 50.2% of patients treated initially with surgery who were found after resection to have nodal disease. There was no significant difference in long-term survival between strategies of primary surgery and induction therapy followed by surgery (median 41.1 versus 41.9 months, p = 0.51). In multivariable analysis, induction therapy was not independently associated with risk of death (hazard ratio [HR], 1.16, p = 0.32). Conclusions: Current clinical staging for early-stage esophageal cancer is highly inaccurate, with only a quarter of surgically resected cT2N0 patients found to have had accurate pretreatment staging. Induction therapy for patients with cT2N0 esophageal cancer in the NCDB is not associated with improved survival.

Comments are closed.